194.38
2.03%
+3.86
Biogen Inc stock is currently priced at $194.38, with a 24-hour trading volume of 1.54M.
It has seen a +2.03% increased in the last 24 hours and a -11.09% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $190.9 pivot point. If it approaches the $195.3 resistance level, significant changes may occur.
Biogen Inc Stock (BIIB) Financials Data
Biogen Inc (BIIB) Revenue 2024
BIIB reported a revenue (TTM) of $9.84 billion for the quarter ending December 31, 2023, a -3.32% decline year-over-year.
Biogen Inc (BIIB) Net Income 2024
BIIB net income (TTM) was $1.16 billion for the quarter ending December 31, 2023, a -61.89% decrease year-over-year.
Biogen Inc (BIIB) Cash Flow 2024
BIIB recorded a free cash flow (TTM) of $1.24 billion for the quarter ending December 31, 2023, a +8.30% increase year-over-year.
Biogen Inc (BIIB) Earnings per Share 2024
BIIB earnings per share (TTM) was $7.98 for the quarter ending December 31, 2023, a -61.87% decline year-over-year.
Biogen Inc Stock (BIIB) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Singhal Priya | Head of Development |
Apr 02 '24 |
Sale |
213.09 |
93 |
19,817 |
4,886 |
Murphy Nicole | Head of Pharm Ops and Tech |
Apr 01 '24 |
Option Exercise |
0.00 |
240 |
0 |
9,751 |
Singhal Priya | Head of Development |
Feb 22 '24 |
Sale |
221.23 |
262 |
57,962 |
4,886 |
Singhal Priya | Head of Development |
Feb 16 '24 |
Option Exercise |
0.00 |
1,208 |
0 |
5,429 |
ALEXANDER SUSAN H | EVP Chief Legal Officer |
Feb 16 '24 |
Option Exercise |
0.00 |
5,037 |
0 |
52,506 |
Gregory Ginger | EVP, Human Resources |
Feb 16 '24 |
Option Exercise |
0.00 |
4,704 |
0 |
14,341 |
Izzar Rachid | Head of Global Product Strat. |
Feb 16 '24 |
Option Exercise |
0.00 |
2,017 |
0 |
10,014 |
Kramer Robin | Chief Accounting Officer |
Feb 16 '24 |
Option Exercise |
0.00 |
1,345 |
0 |
6,354 |
MCDONNELL MICHAEL R | EVP, Chief Financial Officer |
Feb 16 '24 |
Option Exercise |
0.00 |
6,720 |
0 |
20,692 |
Murphy Nicole | Head of Pharm Ops and Tech |
Feb 16 '24 |
Option Exercise |
0.00 |
1,260 |
0 |
9,624 |
Biogen Inc Stock (BIIB) Latest News
What's in Store for Biogen (BIIB) This Earnings Season?
Zacks Investment Research
Gear Up for Biogen (BIIB) Q1 Earnings: Wall Street Estimates for Key Metrics
Zacks Investment Research
Sage (SAGE) Down 20% on Parkinson's Study Missing Primary Goal
Zacks Investment Research
Analysts Estimate Gilead Sciences (GILD) to Report a Decline in Earnings: What to Look Out for
Zacks Investment Research
Biogen Inc. (BIIB) Reports Next Week: Wall Street Expects Earnings Growth
Zacks Investment Research
Where Biogen Stands With Analysts
Benzinga
About Biogen Inc
Biogen Inc. discovers, develops, manufactures, and delivers therapies for the treatment of neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis (MS); FUMADERM for the treatment of plaque psoriasis; and SPINRAZA to treat spinal muscular atrophy. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), and other conditions; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies. In addition, the company is developing BAN2401, which has completed Phase II clinical trial for the treatment of Alzheimer's disease, as well as Elenbecestat that is in Phase III clinical trial for treatment of early Alzheimer's disease. The company's Phase II clinical trial products comprise Opicinumab for MS; BIIB092 for PSP; Natalizumab for Acute Ischemic Stroke and Epilepsy; and BG00011 for idiopathic pulmonary fibrosis. Its Phase I/IIa clinical trial products consist of BIIB080 for patients with mild Alzheimer's disease. The company's Phase I clinical trial products comprise Aducanumab for Alzheimer's disease; BIIB076, an anti-tau monoclonal antibody; and BIIB054 for Parkinson's disease. Biogen Inc. offers products through its sales force and marketing groups. It has strategic collaboration with Ionis Pharmaceuticals to develop drug candidates for neurological diseases. The company was formerly known as Biogen Idec Inc. and changed its name to Biogen Inc. in March 2015. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Cap:
|
Volume (24h):